Hydroxyphenyllactic acid
|
Basic information |
| Metabolite name | Hydroxyphenyllactic acid |
 | HMDB0000755 |
 |
C03672 |
 |
9378 |
| Synonyms | 4-hydroxyphenyllactic acid; |
| No. of studies | 7 |
|
Basic information |
| Metabolite name | Hydroxyphenyllactic acid |
| HMDB0000755 |
|
C03672 |
|
9378 |
| Synonyms | 4-hydroxyphenyllactic acid; |
| No. of studies | 7 |
|
Relationship between Hydroxyphenyllactic acid and depression (count: 7) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M011 | Type4 | sertraline-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M037 | Type2 | placebo treatment group one-week vs. baseline | Serum | Human | Up |
| Study M037 | Type2 | placebo treatment group four-week vs. baseline | Serum | Human | Up |
| Study M037 | Type2 | sertraline treatment group one-week vs. baseline | Serum | Human | Up |
| Study M037 | Type2 | sertraline treatment group four-week vs. baseline | Serum | Human | Up |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Up |
| Study M686 | Type1 | depression group vs. control group | Urine | Human | Down |